Sarah Schellhorn, MD
Medical Oncology · New Haven, CTNPI 1033386891
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $46,593 of the $51,161 with a category attached, or 91.1%. Eisai Inc. accounts for 72.3% of it on its own, with 5 other manufacturers making up the rest. Reporting peaked in 2019 at $16,082 and has fallen 99.8% since, to $37 in 2025.
Across 24 payments — averaging $2131.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eisai Inc.$37K
- Eisai CO., LTD.$11K
- Seagen Inc.$2K
- Bristol Myers Squibb$1K
- Caris MPI, Inc.$37
- Gilead$12
Across 78 payments — averaging $3309.51 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Gilead$223K
- Immunomedics, Inc.$32K
- Merck$2K
- Genentech, Inc.$900
What the payments were for
- Consulting fees$46,59391%
- Speaking & faculty fees$4,2698%
- Travel & lodging$230%
- Food & beverage$2641%
- Education$120%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eisai Inc. | 15 | $36,999 |
| Eisai CO., LTD. | 4 | $10,938 |
| Seagen Inc. | 1 | $1,925 |
| Bristol Myers Squibb | 2 | $1,250 |
| Caris MPI, Inc. | 1 | $37 |
| Gilead | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$51,161 in reported general payments places this provider in the 75th percentile of 79 medical oncology providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Exemestane | 19 | $3,477 |
| Anastrozole | 131 | $2,411 |
| Letrozole | 24 | $728 |
| Tamoxifen Citrate | 21 | $560 |
| Ondansetron OdtOndansetron | 13 | $315 |
| Gabapentin | 14 | $198 |
Paid to pharmacies, not to this prescriber.
Other medical oncology in New Haven
- Peter MarksNew Haven$578K
- Daniel PetrylakNew Haven$446K
- Mandar MuzumdarNew Haven$371K
- Barbara BurtnessNew Haven$297K
- Ian KropNew Haven$219K
- Francine FossNew Haven$193K
- Anne ChiangNew Haven$158K
- Mario SznolNew Haven$157K
- Lajos PusztaiNew Haven$152K
- Howard HochsterNew Haven$133K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.